Toward Comprehensive Care for Long Covid - New England Journal of Medicine 2023

Three years into the Covid pandemic, SARS-CoV-2 is still with us. As the virus evolves, it continues to pose a health threat in terms of both acute infections (or reinfections) and postacute sequelae. In regard to the former, there is evidence that several pharmacologic interventions reduce the severity of infections, lessen morbidity, and lower mortality. Prevention programs have also been successful in reducing overall infection rates. These efforts can be traced in part to colossal federal support for work ranging from vaccine development to clinical trials to nationwide educational endeavors. Such impressive support is all the more striking in contrast to the void in patient care for a SARS-CoV-2 postviral syndrome that may affect 10% or more of infected people.1,2

spike protein

The sequelae of SARS-CoV-2 infection can involve multiple organ systems and are often grouped together as “long Covid” or PASC (postacute sequelae of SARS-CoV-2).3 But the terms themselves are nebulous, the clinical presentations extremely variable, and the prognosis uncertain.4,5 The absence of evidence-based treatments further fuels the frustration of affected patients and their clinicians. Add to these problems our shaky and fragmented health care system, additionally wobbled by the pandemic, and the result is disarray in our approach to this complex and multifaceted disorder.

The extent of the symptom complex of long Covid is unknown, in part because there is no well-accepted definition of the syndrome and because of the relatively poor penetration of care to marginalized populations that have been disproportionately affected by the pandemic. The Centers for Disease Control and Prevention (CDC) defines long Covid as a wide range of new, returning, or ongoing health problems occurring more than 4 weeks after someone becomes infected with SARS-CoV-2. The World Health Organization (WHO) does not fully define long Covid but classifies it by continuation or onset of new symptoms 3 months after the original bout of illness or positive test.

In October 2021, the world adopted International Classification of Diseases code U09.9 to help clinicians document visits of patients with long Covid. Basically, one or multiple symptoms persisting or occurring more than 4 weeks after the onset of acute SARS-CoV-2 infection are coded as U09.9. Signs and symptoms include shortness of breath, fatigue with or without exertion, myalgia, glucose intolerance, multisystem inflammatory syndrome, postural orthostatic tachycardia, peripheral neuropathy, and others reflective of multi–organ-system involvement.4,5 Although this categorization is helpful for research and tracking of electronic health records, it does little to help clinicians or affected people make their way through a maze of difficulties from diagnosis to treatment.

The pathophysiology of long Covid remains elusive, in part because of the multiple possible signs, symptoms, and organ systems involved.3 A lack of understanding of long Covid inevitably also complicates care. Long Covid clinics have been established to provide multidisciplinary care, although most affected patients are also followed by primary care providers or seen by various specialists, depending on the duration and severity of their dominant symptoms. Educational programs for patients and clinicians are lacking. Referrals to subspecialists such as cardiologists, pulmonologists, and neurologists are common but often lead to more delays, fragmentation of care, and frustration at all levels. Primary care providers feel the brunt of that frustration, both their patients’ and their own at their inability to help beyond deploying simple strategies, such as exercise or nutritional supplementation, that are used as preventive measures for healthy people.

Patients with long Covid are still subject to stigmatization because of perceived simulation or psychosomatization of symptoms. And most people with long Covid do not feel empowered to take control of their care. At the state and local levels, referral centers that focus on long Covid management are not only sparse and unevenly distributed, but also generally overbooked, difficult to access, and frequently far from patients’ homes. Moreover, there are few or no available treatment options that have been rigorously tested in clinical trials.

On the national level, as part of the initial federal response to long Covid, the National Institutes of Health launched the Researching COVID to Enhance Recovery (RECOVER) initiative (in which we are investigators), which selected a network of enrollment sites (hubs) that cover adults, pregnant people, and children in 33 states, the District of Columbia, and Puerto Rico. In the initial phase of RECOVER, each adult hub worked with community partners to enroll more than 12,000 participants whose clinical tests and data on characteristics are collected in associated biobanks and databases. The goal of adult RECOVER is threefold: to define the clinical spectrum and pathophysiology of long Covid, to determine its natural history and prevalence, and to characterize the way in which SARS-CoV-2 causes postacute sequelae.

In the adult RECOVER longitudinal study, the vast majority of participants were infected with SARS-CoV-2, although a small percentage were recruited as uninfected controls. Some but not all continue to have chronic sequelae from that infection. The second phase of adult RECOVER will involve a limited number of clinical trials for patients with long Covid. Similar trials are planned for RECOVER’s child cohort. In our view, this research initiative is comprehensive and scientifically sound. But many participants have conveyed to investigators their frustration with the fact that delivery of both their primary and specialty health care is, at best, dissociated from RECOVER and in many cases is fragmented, poorly coordinated, or even nonexistent.

RECOVER is a building block for ultimately establishing the clinical definition of long Covid. We believe that over and above this research effort, the country needs additional structures that can provide the capacity for clinicians, patients, caregivers, advocacy groups, employers, and government officials to learn about, adapt, and implement interventions, therapeutics, and other best practices to combat long Covid.

We suggest that this effort include several key features. First, it should support people with long Covid by coordinating clinical care and rehabilitation, reducing health care disparities, and addressing ongoing and complex medical and psychosocial needs, with a particular focus on patients who currently receive fragmented care or no care at all. Such support could be provided by means of national long Covid centers of excellence. This program could begin by building out some centers involved in RECOVER so that they not only collect data and follow participants, but also provide comprehensive care for those patients and others with long Covid. RECOVER serves a cross section of underserved communities through research centers in both urban and rural areas and can act as a bridge to care provision for these patients.

Second, we need to define, continuously improve, and implement standards of care and best practices, built on evidence obtained through a coordinated exchange of information. Third, we can leverage innovative methods for disseminating information and providing support in order to educate clinicians, patients, and communities; broaden access to high-quality care; and further reduce disparities. And fourth, we will need to develop and implement workforce training programs for clinicians caring for patients with long Covid.

To implement such an ambitious program, we strongly urge Congress to consider appropriating funding in fiscal year 2024 for the Health Resources and Services Administration to competitively select centers of excellence in long Covid care by leveraging and expanding the initial investment in RECOVER hubs and other federally supported long Covid activities.

In addition, such centers could support and leverage, both nationally and throughout their states, greater educational initiatives from the CDC and the WHO for both clinicians and patients. Some examples include continuing education programs, grand rounds, and the Project ECHO (Extension for Community Healthcare Outcomes) model, a scalable and effective way of using electronic media to inform and facilitate changes in health and education for clinicians. These efforts should focus on symptom complexes, potential complications, and management strategies. We need to demystify the disease and empower affected people, involving them actively in their own care and in education and training. We also recommend that insurance providers reexamine criteria for disability claims and urge employers to gain a better understanding of this disorder and its wide-ranging implications. Most important, we need to put people and communities, not diseases, at the center of our health systems and empower them to take charge of their own health rather than be passive recipients of services.

If the prevalence of long Covid is indeed between 5 and 15%, we will continue to face an enormous challenge to our national health and our health care system moving forward. Innovative approaches will be needed to care for patients with long Covid, and these need to be backed by education, research, and support at all levels. It’s about time. 

References (5)

  1. 1.Bull-Otterson LBaca SSaydah S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years — United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep 2022;71:713-717 ( opens in new tab).

  2. 2.Al-Aly ZBowe BXie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022;28:1461-1467.

  3. 3.Sherif ZAGomez CRConnors TJHenrich TJReeves WB, RECOVER Mechanistic Pathway Task Force. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife 2023;12:e86002-e86002.

  4. 4.Davis HEAssaf GSMcCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019-101019.

  5. 5.Ceban FLing SLui LMW, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun 2022;101:93-135.

Reposted from:


Popular posts from this blog

Dr Peter McCullough: How to Detox Spike Protein from Body

Dr Peter McCullough: Povidone Iodine, Oral and Nasal Hygiene (2024)

Dr Peter McCullough Early Treatment Protocol

Find a Doctor to prescribe Hydroxychloroquine, Ivermectin and Early Outpatient Treatments (2024)

FLCCC I-Recover Protocol: Post Vaccine Treatment Protocol (March 2024)

How to Make Povidone Iodine 1% Nasal Spray (2024)

Quercetin and Zinc: Zelenko Treatment Protocol

Front Line Doctors Ivermectin Protocol for Prevention and Treatment of COVID-19 (2023)

America's Frontline Doctors Early Treatment Protocol and Contact a Physician 2023

Dr Peter McCullough: Vaccine Shedding and Spike Protein


Show more


Show more